SCHEDULE: Capitalink Discloses 5% Stake in Clearmind Medicine

Capitalink Ltd. has reported a 5.0% beneficial ownership stake in Clearmind Medicine Inc., including shares from a convertible note and warrant.

Summary

• Capitalink Ltd. beneficially owns 107,943 common shares of Clearmind Medicine Inc.
• This represents 5.0% of Clearmind Medicine Inc.'s common shares outstanding, based on 2,088,806 shares as of the reporting date.
• The ownership includes 32,693 directly held common shares.
• It also includes shares potentially acquirable from a convertible promissory note (principal $116,538.50, conversion price $1.25) and a pre-funded warrant.
• Both the convertible note and the pre-funded warrant contain a blocker provision, preventing conversion or exercise if it would result in Capitalink Ltd. owning more than 4.99% of Clearmind Medicine Inc.'s ordinary shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has taken a 5% stake, indicating confidence. However, the passive nature and blocker provision limit immediate implications for control or aggressive activism.

Positives

• A significant 5.0% beneficial ownership stake by Capitalink Ltd. could signal confidence in Clearmind Medicine Inc.'s future prospects.

Negatives

• The blocker provision limits Capitalink Ltd.'s immediate ability to increase its ownership beyond 4.99% through the conversion of the note or exercise of the warrant, potentially capping their influence.

Risks

• Potential future dilution for existing shareholders if Capitalink Ltd. converts the full amount of the convertible note and exercises the pre-funded warrant, assuming the blocker provision eventually allows for it or is waived/modified.
• The existence of a blocker provision at 4.99% indicates a strategic decision to avoid certain regulatory thresholds, which could limit the reporting person's ability to exert greater influence.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Clearmind Medicine Inc.'s operational or financial performance.

Management Comments

• Lavi Krasney, Chief Executive Officer of Capitalink Ltd., certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment stake, typically by institutional investors, and does not inherently suggest a change in company strategy or operations. The presence of a blocker provision is a common mechanism for investors to maintain a significant stake without triggering more stringent reporting requirements or control-related regulations.

Corporate Governance

Stakeholder Impact

• Existing shareholders may experience potential dilution if the convertible note and warrant are fully converted/exercised in the future, although currently limited by the blocker provision.
• The presence of a significant institutional investor like Capitalink Ltd. could provide a level of market validation for Clearmind Medicine Inc.

Next Steps

• Capitalink Ltd. may convert portions of the convertible promissory note or exercise the pre-funded warrant within 60 days, subject to the 4.99% blocker provision.

Key Dates

Keywords

Clearmind Medicine Inc., Capitalink Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Convertible Note, Pre-funded Warrant, Equity Stake, SEC Filing